Effect of pharmacological modulation of liver P-glycoproteins on cyclosporin A biliary excretion and cholestasis - A study in isolated perfused rat liver
M. Delle Monache et al., Effect of pharmacological modulation of liver P-glycoproteins on cyclosporin A biliary excretion and cholestasis - A study in isolated perfused rat liver, DIG DIS SCI, 44(11), 1999, pp. 2196-2204
In different cell types P-glycoproteins (P-gp) are involved in the transpor
t of cyclosporin A (CyA). The aim of this study was to evaluate the effect
of the pharmacological modulation of the hepatic P-gp on biliary secretion
of CyA and on cholestasis induced by acute administration of CyA in the iso
lated perfused rat liver (IPRL). Verapamil was used as a P-gp specific inhi
bitor and acetylaminofluorene (AAF) as a P-gp inducer. CyA biliary excretio
n was determined by administering in the IPRL a tracer dose of [H-3]CyA wit
h or without verapamil or AAF. The effect on bile flow was evaluated by adm
inistering increasing doses of CyA (2.8, 8, and 20 mg/kg body wt) in the IP
RL. Morphological evidence of damage was evaluated by optical and electron
microscopy in the liver as well as in primary culture of rat hepatocytes ex
posed to CyA +/- verapamil. Verapamil significantly inhibited the biliary e
xcretion of a tracer dose of [H-3]CyA (0.15 +/- 0.04 vs 0.33 +/- 0.07%; P <
0.05). In contrast, pretreatment with AAF significantly increased the bili
ary excretion of [H-3]CyA, (0.61 +/- 0.10 vs 0.33 +/- 0.07%; P < 0.05). CyA
induced a dose-dependent inhibition of bile how with a maximal effect at 2
0 mg/kg CyA (-493 +/- 4.5% decrease of basal bile flow). CyA cholestasis wa
s significantly worsened by the P-gp inhibitor, verapamil (-75.5 +/- 7.5%;
P < 0.05), but it was unaffected by induction of P-gp via AAF pretreatment
(-44.9 +/- 1.7%). During CyA cholestasis, the cumulative biliary excretion
of [H-3]CyA was lower than in the absence of cholestasis (0.22 +/- 0.05 vs
0.33 +/- 0.07%; P < 0.05), was inhibited by verapamil (0.08 +/- 0.01%; P <
0.05), but was unaffected by AAF (0.23 +/- 0.05%). No morphological evidenc
e of damage was observed in the liver, and no evidence of cytoskeleton dera
ngement was seen in primary cultures of rat hepatocytes exposed to CyA +/-
verapamil. We demonstrated that pharmacological modulation of P-gp may infl
uence the biliary excretion of CyA. The acute cholestatic effect of CLA is
worsened by P-gp inhibitors, while it is unaffected by P-gp inducers. This
indicates CyA should not be given with other P-gp substrates or inhibitors.